Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection
| Errataetall: |
CommentOn: J Infect Dis. 2021 Aug 16;224(4):586-594. - PMID 33978754 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:224 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 224(2021), 6 vom: 17. Sept., Seite 1097-1099 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choe, Pyoeng Gyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 22.09.2021 Date Revised 31.12.2021 published: Print CommentOn: J Infect Dis. 2021 Aug 16;224(4):586-594. - PMID 33978754 Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiab339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32713710X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32713710X | ||
| 003 | DE-627 | ||
| 005 | 20231225200117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiab339 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM32713710X | ||
| 035 | |a (NLM)34166506 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choe, Pyoeng Gyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2021 | ||
| 500 | |a Date Revised 31.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: J Infect Dis. 2021 Aug 16;224(4):586-594. - PMID 33978754 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Kang, Chang Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Kye-Hyung |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Jongyoun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Eu Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Park, San Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Nam Joong |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Wan Beom |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Myoung-Don |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 224(2021), 6 vom: 17. Sept., Seite 1097-1099 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:224 |g year:2021 |g number:6 |g day:17 |g month:09 |g pages:1097-1099 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiab339 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 224 |j 2021 |e 6 |b 17 |c 09 |h 1097-1099 | ||